ArticleJournal of obesity2011
Pharmacotherapies for obesity: past, current, and future therapies.
Article in Journal of obesity, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 1 synthesis or guideline pooled it, 244 citations in OpenAlex.
- Naltrexone sustained-release/bupropion sustained-release for the management of obesity: review of the data to date.Drug design, development and therapy · 2014Pooled it
- A comparative study of five centrally acting drugs on the pharmacological treatment of obesity.International journal of obesity (2005) · 2014Trial
- From Adipose Tissue Dysfunction to Venous Thromboembolism.Journal of clinical medicine · 2026Review
- Evaluation of Aqueous Maceration and Ultrasound-Assisted Extracts ofPharmaceuticals (Basel, Switzerland) · 2025Article
- Targeted Nano-Based Systems for the Anti-Obesity Agent's Delivery.Advances in experimental medicine and biology · 2024Review
- Recent advancements in pharmacological strategies to modulate energy balance for combating obesity.RSC medicinal chemistry · 2023Review
- Management of Obesity and Obesity-Related Disorders: From Stem Cells and Epigenetics to Its Treatment.International journal of molecular sciences · 2023Review
- Traveling across Life Sciences with Acetophenone-A Simple Ketone That Has Special Multipurpose Missions.Molecules (Basel, Switzerland) · 2023Review
- The Effect of Smoking Cessation on Body Weight and Other Metabolic Parameters with Focus on People with Type 2 Diabetes Mellitus.International journal of environmental research and public health · 2022Review
- Serotonin and beyond-a tribute to Manfred Göthert (1939-2019).Naunyn-Schmiedeberg's archives of pharmacology · 2021Review
- Nodakenin represses obesity and its complications via the inhibition of the VLDLR signalling pathway in vivo and in vitro.Cell proliferation · 2021Article
- Practical Approaches to Treating Obesity: Patient and Healthcare Professional Perspectives.Advances in therapy · 2021Article
- Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)-A Condition Associated with Heightened Sympathetic Activation.International journal of molecular sciences · 2021Review
- Current Long-Term Pharmacotherapies for the Management of Obesity.Journal of obesity & metabolic syndrome · 2020Review
- Diet aid or aid to die: an update on 2,4-dinitrophenol (2,4-DNP) use as a weight-loss product.Archives of toxicology · 2020Review
- Comparing the Study Populations in Dietary Supplement and Drug Clinical Trials for Metabolic Syndrome and Related Disorders.AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science · 2019Article
- Gold nanoparticles as cell regulators: beneficial effects of gold nanoparticles on the metabolic profile of mice with pre-existing obesity.Journal of nanobiotechnology · 2018Article
- Prenatal Exposure to Gestational Nicotine before Neurulation is Detrimental to Neurodevelopment of Wistar Rats' Offspring.The Malaysian journal of medical sciences : MJMS · 2018Article
- Vascular targeted nanotherapeutic approach for obesity treatment.International journal of nanomedicine · 2018Review
- Pharmabiotics as an Emerging Medication for Metabolic Syndrome and Its Related Diseases.Molecules (Basel, Switzerland) · 2017Review
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Past therapies for the treatment of obesity have typically involved pharmacological agents usually in combination with a calorie-controlled diet. This paper reviews the efficacy and safety of pharmacotherapies for obesity focusing on drugs approved for long-term therapy (orlistat), drugs approved for short-term use (amfepramone [diethylpropion], phentermine), recently withdrawn therapies (rimonabant, sibutamine) and drugs evaluated in Phase III studies (taranabant, pramlintide, lorcaserin and tesofensine and combination therapies of topiramate plus phentermine, bupropion plus naltrexone, and bupropion plus zonisamide). No current pharmacotherapy possesses the efficacy needed to produce substantial weight loss in morbidly obese patients. Meta-analyses support a significant though modest loss in bodyweight with a mean weight difference of 4.7 kg (95% CI 4.1 to 5.3 kg) for rimonabant, 4.2 kg (95% CI 3.6 to 4.8 kg) for sibutramine and 2.9 kg (95% CI 2.5 to 3.2 kg) for orlistat compared to placebo at ≥12 months. Of the Phase III pharmacotherapies, lorcaserin, taranabant, topiramate and bupropion with naltrexone have demonstrated significant weight loss compared to placebo at ≥12 months. Some pharmacotherapies have also demonstrated clinical benefits. Further studies are required in some populations such as younger and older people whilst the long term safety continues to be a major consideration and has led to the withdrawal of several drugs.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.